Xencor regains rights to XmAb5871 from Amgen

29 October 2014

US drug developer Xencor (Nasdaq: XNCR) revealed yesterday that it has regained all development and commercial rights to XmAb5871 from Amgen (Nasdaq: AMGN), the world’s largest independent biotech company.

Xencor says it sought and obtained a termination of the prior option and collaboration agreement and executed a new right-of-first-negotiation agreement with Amgen. The original deal could have been worth as much as $500 million to the company (The Pharma Letter January 7, 2011).

XmAb5871 is a first-in-class monoclonal antibody containing Xencor's proprietary immune inhibitor XmAb Fc domain that targets Fc RIIb to inhibit B-cell function. XmAb5871 is currently in a Phase Ib/IIa clinical trial in patients with moderate-to-severe rheumatoid arthritis (RA) and top-line results are expected by the end of 2014. The company is planning clinical development in multiple autoimmune diseases where B-cell inhibition shows promise, including IgG4-related disease.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK